Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1

Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill ...

2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026?

2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? Eli Lilly is currently ...
The Daily Star

Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand

A more than 35% rally in the company's stock this year has largely been driven by the explosive growth of the weight-loss ...
NDTV Profit

Lilly Joins $1 Trillion Club In Weight-Loss Drug Fueled Climb

Shares of Lilly rose as much as 1.7% on Friday, pushing its market value to about $1 trillion, according to data compiled by ...
The Pharma Letter

BRIEF—Lilly is first pharma group to be valued at $1 trillion

US pharma giant Eli Lilly’s weight-loss drugs have made it the first pharma company to hit a $1 trillion market valuation, a sharp turnaround from this summer when its stock was hit by disappointing ...